@alphaclubsupps's TRT dosing claims, fact-checked

What did @alphaclubsupps actually say?

The creator's core argument is straightforward: 250mg of testosterone per week pushes most men well outside normal physiological testosterone ranges, making it a cycle dose rather than genuine TRT. He states that "for 99.9% of guys 250 is putting you way outside" normal ranges, and flags E2, prolactin, and hematocrit as the downstream problems. He stops short of calling it a full cycle, describing it as "borderline."

He also claims standard TRT lands around 75-150mg per week, and that individual tolerance claims from his audience, the "I run it and I've got no problems" crowd, don't negate population-level risks. He's asking for nuance in how people label their hormone use. That's a reasonable thing to ask for, even if some of the supporting details are imprecise.

Does the science back this up?

Mostly, yes. The claim that 250mg/week exceeds physiological testosterone ranges for the vast majority of men is well-supported. The question is how far outside normal it goes, and the literature is pretty clear on that.

A landmark study by Bhasin et al. (2001, New England Journal of Medicine) demonstrated that 600mg/week of testosterone enanthate in healthy men produced supraphysiological levels and significant increases in muscle mass and strength, well beyond what exogenous replacement targeting normal ranges would produce. At 250mg/week, you're not at that extreme, but you're not in therapeutic territory either for most men.

More relevantly, the Endocrine Society's clinical practice guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) recommend targeting mid-normal physiological testosterone levels, roughly 400-700 ng/dL, using the lowest effective dose. Typical doses achieving that in clinical practice range from 75mg to 200mg per week of testosterone cypionate or enanthate, with many patients responding within normal range at 100-150mg. Getting to 250mg/week routinely produces total testosterone well above 1000-1200 ng/dL in most men, which is supraphysiological by any standard reference range.

His concerns about erythrocytosis (he called it "hermeticret," almost certainly meaning hematocrit) are also legitimate. Calof et al. (2005, Journals of Gerontology) found dose-dependent increases in hematocrit with testosterone use, with higher doses carrying proportionally higher cardiovascular risk signals.

What did they get wrong (or right)?

He got the central claim right. 250mg/week is not standard therapeutic dosing for hypogonadism by any major clinical guideline. Giving him credit for that directly: the framing is accurate, and he's pushing back against a real and widespread misconception in fitness communities where supraphysiological dosing gets laundered as medical TRT.

What he got imprecise: the "99.9% of guys" figure is rhetorical, not clinical. There is no published threshold data that quantifies exactly what percentage of men exceed normal ranges at 250mg/week, though the pharmacokinetic evidence strongly supports his directional point. Individual variation in testosterone metabolism, SHBG levels, and injection frequency means the number isn't literally 99.9%, even if it's very high.

His pronunciation of "hematocrit" aside, his grouping of E2, prolactin, and hematocrit as concerns at this dose is clinically reasonable but slightly imprecise. Prolactin elevation is more commonly associated with aromatization products and estrogen excess than testosterone dose directly, and the relationship is more indirect than he implies. E2 and hematocrit elevation are more directly dose-dependent.

He does not recommend a specific dose himself, which is appropriate for a social media context. That's worth noting.

What should you actually know?

If you are prescribed testosterone for diagnosed hypogonadism, your prescribing clinician should be titrating your dose to bloodwork, not to a fixed number. A therapeutic goal is a serum testosterone level in the mid-normal physiological range, not a weekly milligram target in isolation.

The distinction between TRT and performance-enhancing testosterone use is not just semantic. It has real implications for cardiovascular risk, fertility, erythrocytosis, and long-term endocrine function. Rastrelli et al. (2018, Best Practice and Research: Clinical Endocrinology and Metabolism) reviewed the cardiovascular risk profile of testosterone therapy and found that dose and hematocrit elevation were among the most clinically significant monitoring targets.

If you are on a dose of 250mg/week under a telehealth prescription and have not had recent bloodwork including total testosterone, free testosterone, estradiol, hematocrit, and PSA, that is a problem worth raising with your provider directly. Legitimate TRT protocols require monitoring. A dose that is never adjusted against labs is not a therapeutic protocol, it is a fixed dosing scheme.

• Normal physiological testosterone range in adult men: approximately 300-1000 ng/dL depending on lab reference range.
• Endocrine Society guidelines target mid-normal range with the lowest effective dose.
• 250mg/week typically produces supraphysiological levels in most men based on pharmacokinetic data.
• Erythrocytosis is a dose-dependent risk that requires periodic hematocrit monitoring.